Context Therapeutics Q3 net loss $9.7M; early clinical data for CTIM-76 and CT-95

Context Therapeutics Inc.

Q3 net loss $9.7M, down from $17.5M YoY; cash $76.9M sufficient into 2027.
CTIM-76 Phase 1: 12 patients; RECIST response observed from Cohort 3; no CRS>Grade1, no DLT.
CT-95 Phase 1: 6 patients; approaching target dose with Cohort 4; no CRS>Grade2.
CT-202 (Nectin-4 x CD3) preclinical; expects regulatory filing for first-in-human trial in Q2 2026.
Anticipates updated CTIM-76 Phase 1a data and Phase 1b dose selection in Q2 2026; CT-95 data mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.